Computational analysis of envelope glycoproteins from diverse geographical isolates of bovine leukemia virus identifies highly conserved peptide motifs
© The Author(s) 2018
Received: 12 September 2017
Accepted: 23 December 2017
Published: 8 January 2018
Bovine leukemia virus (BLV) is a deltaretrovirus infecting bovine B cells and causing enzootic bovine leucosis. The SU or surface subunit, gp51, of its envelope glycoprotein is involved in receptor recognition and virion attachment. It contains the major neutralizing and CD4+ and CD8+ T cell epitopes found in naturally infected animals. In this study, we aimed to determine global variation and conservation within gp51 in the context of developing an effective global BLV vaccine.
A total of 256 sequences extracted from the NCBI database and collected in different parts of the world, were studied to identify conserved segments along the env gene sequences that encode the gp51 protein. Using the MEME server and the conserved DNA Region module for analysis within DnaSP, we identified six conserved segments, referred to as A–F, and five semi-conserved segments, referred to as G–K. The amino acid conservation ranged from 98.8 to 99.8% in conserved segments A to F, while segments G to K had 89.6–95.2% conserved amino acid sequence. Selection analysis of individual segments revealed that residues of conserved segments had undergone purifying selection, whereas, particular residues in the semi-conserved segments are currently undergoing positive selection, specifically at amino acid positions 48 in segment K, 74 in segment G, 82 in segment I, 133 and 142 in segment J, and residue 291 in segment H. Each of the codons for these six residues contain the most highly variable nucleotides within their respective semi-conserved segments.
The data described here show that the consensus amino acid sequence constitutes a strong candidate from which a global vaccine can be derived for use in countries where eradication by culling is not economically feasible. The most conserved segments overlap with amino acids in known immunodeterminants, specifically in epitopes D–D′, E-E′, CD8+ T-cell epitopes, neutralizing domain 1 and CD4+ T-cell epitopes. Two of the segments reported here represent unique segments that do not overlap with previously identified antigenic determinants. We propose that evidence of positive selection in some residues of the semi-conserved segments suggests that their variation is involved in viral strategy to escape immune surveillance of the host.
Bovine leukemia virus (BLV), which belongs to the Deltaretrovirus genus of the Retroviridae family, is the causative agent of Enzootic Bovine Leukosis (EBL) [1, 2]. The majority of BLV-infected cattle remain asymptomatic throughout their lives. However, about 5–10% of infected animals develop malignant tumors and 30% of infected individuals develop B-cell lymphocytosis characterized by extensive proliferation of CD5+ cells .
Similar to other retroviruses, the genome of BLV contains three major genes, gag, pol and env. The first two genes yield the virion structural proteins and the viral enzymes, including reverse transcriptase. The env gene encodes the envelope glycoprotein precursor (gp72), the viral membrane protein against which neutralizing antibodies would be expected to act. During synthesis, gp72 is cleaved into two associated components, a surface glycoprotein subunit of 51 kDa size (SU, gp51), implicated in receptor recognition and virion attachment, and a transmembrane glycoprotein subunit (TM, gp30) that induces the fusion of viral and cellular membranes necessary for virus to penetrate into host cell cytoplasm [4, 5].
The genetic variation in field isolates of BLV from naturally infected livestock represents a low mutation rate which appears to be less than that of other genera in Retroviridae. The genetic variability of BLV strains is typically analyzed by comparing the proviral sequences present in naturally infected cattle to the reference sequences of the FLK/BLV strain isolated from a BLV-infected foetal lamb kidney cell line (Accession no. M35242.1, USA) or to the field strain (Accession no. K02120, Japan). While the in vivo mutation rates measured on the env genes of BLV and lentiviruses are comparable at 0.009 and 0.0085 nucleotide changes per year, respectively, 81% of the nucleotide changes made by lentivirus reverse transcriptase (RT) are nonsynonomous whereas 50% of the BLV RT errors change the amino acid [6–9]. In vitro, the BLV RT is 10-fold more faithful than other retroviral polymerases and errs on average at an estimated one out of 20,800 nucleotides for an error rate of 4.8 × 10−6 nucleotides compared to 2.5–5.9 × 10−4 for purified HIV-1 RT and 3.4 × 10−5 measured during single cycle HIV-1 infection, 5.9 × 10−5 for avian myeloblastosis RT, 3.3 × 10−5 for Moloney murine leukemia virus RT, and 1.2 × 10−5 nucleotides for avian spleen necrosis virus RT [9–12].
Genetic studies have determined that the level of variation in proviral nucleotide and amino acid sequences is very low among infected cattle from geographically different parts of the world [13–27]. Phylogenetic analysis of the env gene of BLV isolates from these different geographical locations identified ten genotypes, G1–G10 . Even among these ten genotypes the variation is low and only twenty amino acids among the 515 residues in gp72 differ among all the genotypes combined.
The lower non-synonomous mutation rate in BLV infection and very low interstrain variation in the envelope glycoprotein were predicted to be advantageous in developing a BLV vaccine . A number of B-cell and T-cell determinants have been identified on gp51. The antigenic sites are the G, H, and F conformational epitopes, the A, B-B′, D–D′ and E-E′ linear epitopes and three neutralization domains ND1, ND2 and ND3 involved in virus neutralization and syncytium inhibition [28–31]. Five T-cell epitopes (CD4+ T-cell epitope, CD8+ T-cell epitope, gp51N5, gp51N11 and gp51N12) located within gp51 have been shown to be immunologic targets of cytotoxic T lymphocytes (CTL) and involved in induction of proliferative responses in BLV infected cattle [31–33].
The variation of these promising B-cell and T-cell determinants across global isolates has not yet been determined. Here we apply computational analysis of gp51 nucleotide and deduced amino acid sequences from the 256 BLV env gene sequences in the NCBI database to investigate global variation and conservation within SU. The results revealed the presence of highly conserved segments as well as several semi-conserved segments. Together these analyses define a hierarchy of conservation among the sequences of the B-cell and T-cell determinants that will be useful in developing an effective global BLV vaccine.
Identification and selection of segments using MEME and DnaSP analyses
To analyze BLV isolates collected in different parts of the world we mapped conserved segments along the env gene sequence that encodes the gp51 protein. Two hundred and fifty-six sequences encoding residues 1–267 of the 268 amino acids in the mature gp51 surface subunit of BLV isolates representative for all known genotypes (G1–G10) were extracted from the NCBI nucleotide database and used for this study. Sequences were aligned and the alignment submitted to Multiple Expectation Maximization for Motif Elicitation (MEME) to identify sequence patterns or segments that occur repeatedly in the aligned group of 256 sequences analyzed. The MEME server generated twenty blocks of nucleotide sequence that occur once in the gp51 coding sequence and have E-values consistent with a very low probability that the MEME motif (term used interchangeably with a segment) is randomly present in the 256 BLV env genes. Eleven blocks were selected for further analysis based on considerations of four criteria: (1) low probability that the repeated occurrence of the sequence segment was random within the aligned coding sequences of gp51; (2) degree of amino acid conservation; (3) degree of nucleotide conservation; and (4) the genetic distance exhibited within a MEME motif. The eleven MEME motifs range in length from six to nineteen amino acids and have an average length just under twelve amino acids.
The alignment was separately interrogated using the Conserved DNA Region module of DnaSP to identify segments of the nucleotide sequence conservation with the threshold for nucleotide conservation set at 80%. This analysis identified six statistically significant stable segments, with p value < 0.05 and nucleotide sequence conservation greater than or equal to 0.8 (80%). These segments were located exactly within the six blocks of segments A–F identified as nonrandom using MEME analysis. Segments G–J in MEME blocks 16–20 fell below the 80% nucleotide conservation threshold and their p values were not calculated (Fig. 1).
To estimate genetic distances for each of these MEME blocks p distance nucleotide substitution model in the Molecular Evolutionary Genetics Analysis software (MEGA) version 5.2.2. was used. The genetic distance relates to divergence between any two strands of aligned DNA sequences, and it is expressed as the number of nucleotide differences per site. In this study we calculated the overall mean, which is the arithmetic mean of all individual pairwise distances between the sequences under study. The six conserved segments had genetic distances from 0.6 to 1.7%, while distance values from 5.8 to 7.8% characterized segments G–K (Fig. 1). Based on these findings taken together, we grouped segments A–F together as conserved in amino acid and nucleotide sequence and segments G–K as semi-conserved in amino acid sequence.
Evidence of purifying selection in segments A–F and positive selection in segments G–J
Genetic diversity within a coding sequence from a population of related sequences can be assessed by comparing the rates of synonymous and non-synonymous substitutions per site. An excess of non-synonymous mutations suggests selection for change, or positive selection, which is often the result of an antagonistic interaction between a virus and its host. This high genetic variation confers a fitness advantage to the pathogen in its attempt to evade host defenses. In contrast, an excess of synonymous mutations suggests that there is selection against change, or purifying selection, meaning the sequence is likely to be beneficial to the host. The negatively selected sites point to functional constraint, and could be used in vaccine design. The high degree of amino acid and nucleotide sequence conservation of segments A–F among the 256 BLV sequences suggested that these portions of the env gene are very stable during replication and might be undergoing negative or purifying selection associated with predominantly synonymous substitutions. Whereas, the nucleotide variation of segments G–J suggested the possibility that they contained sequences that are less stable and under positive selection. To examine this possibility, the frequency of non-synonymous (dN) and synonymous (dS) nucleotide substitutions per site within each segment was calculated and the ratio dN/dS was estimated.
Selection analysis revealed that the rates of synonymous nucleotide substitutions per site (dS) were higher than the non-synonymous rates (dN) within all analyzed segments showing a high probability of purifying selection. These differences were statistically significant as judged by Z-test (Z-test: p < 0.0001 for A-J segments and p < 0.05 for K segment). The dN/dS values were substantially less than 1 for all segments, also in agreement with the existence of strong purifying selection pressure. Nevertheless, dN/dS values noted for semi-conserved segments G–K were substantially higher than those noted for conserved segments A–F, suggesting the existence of putative sites undergoing positive but not purifying selection.
Computational analyses indicate that conserved MEME motifs G–K of gp51 are under positive selection
Sites of positive selectiond
Ala291, Val291, Thr291
Phe82, Ser82, Leu82
Val133, Thr133, Pro133, Asp133, Ala133, Asp141, Asn141
Thr48, Tyr48, Val48, Ile48
Refinement of the gp51 sequence segment map
In the process of evaluating the sequence segments (MEME motifs), we placed them on the consensus amino acid sequence generated in the initial MEME analysis. It was then apparent that two pairs of conserved MEME motifs, e.g., A and E, and D and F, and one pair of semi-conserved MEME motifs, e.g., G and I, were located very close to each other in the primary sequence. Any of these pairs might actually represent a larger segment that was split up because the maximum MEME motif width was set at 60 nucleotides or 20 amino acid codons in our initial MEME analysis. To determine if this was the case, the 256 gp51-encoding sequences were submitted a second time to the MEME server using a minimum MEME motif width of 60 nucleotides and a maximum width of 99 nucleotides (20–33 amino acid codons). Using these parameters, the output should cover the 268 codons of gp51 almost twice over (minimum length of 20 codons × 25 motif block output = 500 codons). Since all of the segments discovered in the initial analyses are shorter than the minimum 20 amino acid width in the new analysis, we expected that the original A-K MEME motifs would be included in the blocks from this new analysis only if they are part of longer conserved regions.
Long conserved MEME motifs found in BLV gp51 env sequences
Amino acid conservation (%)
Genetic distance (%)
Relationship of segments to known and predicted functional domains of gp51
While the three-dimensional structure for a portion of TM proteins from BLV (gp30) and the human deltaretrovirus HTLV-1 (gp21) have been solved, no structure is available for gp51 or the SU (gp46) from HTLV-1. However, the envelope glycoproteins of both retroviruses belong to the cd09948:Ebola_RSV-like_HR1-HR2 and pfam00429:TLV_coat ENV polyprotein (coat polyprotein) families of glycoproteins which include the envelope glycoproteins of HTLV-1, BLV, the avian retroviruses Rous sarcoma virus and Avian Leukosis Virus subgroup J, Friend Murine Leukemia Virus (Fr57 MLV) and Feline leukemia virus type B (FeLV-B) and Ebola virus [34, 35]. Members of these families contain related functional domains of similar sequence and there is evidence that they use a shared mechanism for attachment and membrane fusion during virus entry based on isomerization of a disulphide bond between the attachment and fusion subunits . Structures from three members of the families have been solved, e.g., that of the established receptor binding domains of gammaretroviruses Fr57 MLV and FeLV-B, and of the ectodomain of the mature envelope glycoprotein from Ebola virus.
While highly speculative, a model based on the alignment of conserved domains previously identified in the cd09948:Ebola_RSV-like_HR1-HR2 and pfam00429:TLV_coat ENV polyprotein (coat polyprotein) families  was also generated. Since the Ebola glycoprotein GP structure is the only structure that includes more than the RBD for a member of these families, its use as the model template afforded an opportunity to model the six segments which are carboxy-terminal to residue 156 of mature gp51 and lie outside the alignments with the RBD of FeLV-B and Fr57 MLV (Fig. 4b). It also could provide insight into segments that are surface-exposed in the RBD model but which are buried in gp51 by residues 197–267 of gp51. This model predicts that the majority of residues within segments A–F are exposed on the surface of the gp51 glycoprotein, including the following residues: 106-VTYDCEPRCPY-116 of segment A, 194-PSVRS-197 of segment B, 256-TQGWHHPSQRLL-269 of segment C, as well 164-GYDP-167 of segment F. Conversely, conserved segments D and E as well as residues 198-WALLLNQ-204 in segment B are predicted to be buried in a beta-strand within the core of the structure in the model shown in Fig. 4b.
Since the discovery of BLV as the causative agent in EBL in 1969 , efforts at global elimination of BLV have centered on testing and removal of infected animals from herds as the preferred method of eradication of the disease. This strategy has achieved eradication in some countries particularly those with a low initial prevalence of BLV-infected cattle. However, EBL remains endemic in locations where the high prevalence rate is an economic barrier to the culling strategy and large numbers of cattle exhibit the most common clinical manifestation of BLV infection, persistent lymphocytosis. These locations include North and South America, Middle Eastern and Southeast Asian nations and the Caribbean region (OIE World Animal Health Organization from the years 2015 and 2016). The genetic selection of cattle resistant to BLV infection might be beneficial for minimizing economic losses by reducing disease severity but not for eradication because it currently appears that complete resistance to BLV cannot be obtained by selection of cattle with BLV-resistant alleles of the DRB3.2 gene [37, 38].
A vaccine that protects against BLV transmission would provide an economical alternative method of eradication in countries with high prevalence rates, but the prospect for a preventive or therapeutic anti-deltaretrovirus vaccine are uncertain [39, 40]. One way to make an anti-BLV vaccine would be a peptide-based strategy consisting of highly conserved immunogenic peptide constructs capable of eliciting broadly neutralizing antibody responses [40–42].
The initial goals of our study were to determine a consensus gp51 amino acid sequence for BLV isolates from endemic locations all over the world, identify which, if any, of the known BLV antigenic determinants within glycoprotein gp51 are conserved globally within and between all known genotypes, and to gain insights into the evolution of BLV gp51 during natural in vivo infection particularly with respect to known neutralizing domains and antibody and T-cell epitopes. Toward this objective, all primary isolate sequences that contain at least the coding sequence of residue 1–297 of the 298 residues in mature gp51 were mined from the NCBI public database and submitted to computational analysis from which a consensus amino acid sequence was obtained (Additional file 1: Table S1).
Based on the results reported here, we draw five conclusions. First, we conclude that the consensus amino acid sequence derived from MEME analysis represents the primary consensus sequence of global BLV gp51. The set of 256 proviruses used to generate the consensus sequence represents nucleotide sequences isolated from infected cattle in twenty-one countries and includes isolates from all of the ten known BLV genotypes.
Second, we propose to classify the new segments exhibiting DNA conservation greater than or equal to 80% and genetic distances ranging less than or equal to 3.0% as conserved, and those showing less than 80% DNA conservation and a somewhat higher degree of variability greater than or equal to 4.6% as semi-conserved. Based on these criteria, gp 51 contains six highly conserved segments and five semi-conserved segments of five to twenty residues in length that are distributed throughout gp51. Two pairs of conserved segments (A and E, and D and F) were found to be part of larger conserved segments I and II, respectively, when the analysis parameters were set for segments of longer length (20–33 amino acids) than in our initial analyses. Similarly, semi-conserved segments G and I were found to be part of a larger semi-conserved segment VI.
Third, we conclude that among the segments reported here, only the conserved ones exhibited evidence of purifying selection of their sequences, e.g., dN/dS ratios of substantially less than 1 (≤ 0.182). These relatively low levels of variability reflect a general feature of BLV genomes, that is, its characteristically high degree of conservation among different strains. Low variability among strains is also characteristic of other viruses belonging to the genus Deltaretrovirus [6, 12]. It was recently shown that the homology of the env gene was 94.5–97.7% amongst BLV isolates representative of the ten genotypes . This level of variability is much lower than that reported for conserved regions identified in studies by others of human cytomegalovirus or herpes simplex virus type 1 [43, 44].
We favor that the purifying selection during evolution of the conserved segments suggests that these segments may contain critical core structure sequences, or sequences that interface with the TM gp30, or codons for the residues that interact with the BLV entry receptor. The homology models predict that part of the core structure of the RBD is formed by conserved segments D and F. In the models these segments form adjacent beta-strands previously proposed to face inward toward the trimer interface . The presence of the previously recognized small motif CXXC in large conserved segment IV identifies this segment as containing residues in the gp51:gp30 heterodimer interface. In native envelope glycoprotein on virions, one of the cysteine residues in CXXC motif of gp51 is covalently bound to a cysteine in the conserved CX6CC motif of gp30 and makes an essential contribution to the association of gp51:gp30 heterodimers [45, 46]. In addition, the C-terminal domain of HTLV-1 surface subunit has been reported to be involved in transducing the envelope activation signal upon receptor binding [47, 48], suggesting that conserved segment C in the analogous domain of gp51 may also participate in activation of membrane fusion.
With respect to residues that interact with the BLV entry receptor, neither the receptor nor the gp51 residues with which it interacts are known. However the location of the BLV RBD within the amino-terminal 156 residues of the mature BLV gp51 subunit is supported by homology to the established RBD of the HTLV-1 and the gammaretroviruses [35, 49, 50] and the positions of the proline rich region and the conserved CXXC motif in gp51 . Assuming that all strains of BLV use a common entry receptor, it is most likely that the receptor binding site lies within a highly conserved segment. Four conserved (A, D, E and F) and four semi-conserved segments (G, I, K and J) lie within the first 156 residues (Fig. 3).
We favor that the binding site for the receptor includes conserved segments A and E for the following reasons. First, the receptor binding site is likely to be within or adjacent to a neutralizing domain. There are two neutralizing domains within residues 1–156, ND1 and ND2. Two segments overlap with these domains: segment A overlaps with the C-terminal two-thirds of ND1 and segment J overlaps with the N-terminal two-thirds of ND2. Second, the receptor binding site is likely to be located on the analogous surface to that of the established sites on the Fr57 MLV and Fe-LV-B RBDs. The homology models of gp51 based on these two RBD structures predict that segment A lies on the analogous surface whereas all but the first three residues of segment J are predicted to be buried within the core of the model. Lastly, while segment E is not included in a known neutralizing domain, the homology models predict that it lies beside segment A and that together they form a convex surface comparable in size and predicted location to the known receptor binding sites of Fr57 MLV and FeLV-B. In agreement with this last prediction by the models, analysis for segments of 20–33 amino acid length identified segments A and E as belonging to a single long conserved segment I.
Fourth, we conclude that amino acid positions 48 in segment K, 74 in segment G, 82 in segment I, 133 and 142 in segment J, and residue 291 in segment H are undergoing positive selection. Each of the codons for these six particular residues contains the most highly variable nucleotides within their respective semi-conserved segments. We favor that the genetic evidence of positive selection in these residues is consistent with viral evolution to escape immune surveillance as judged by the location of each of the six residues within known epitopes and neutralizing domains. Residues 48, 74 and 82 comprise three of the four amino acids in conformational epitope G, residues 133 and 142 are located in ND2 (which overlaps with the Zinc binding peptide), and residue 291 is in epitope A.
It has been postulated that some divergent residues within conserved segments may be under positive selection [32, 51]. Zhao and coworkers investigated possible selection over the entire glycoprotein sequence from forty-four unique isolates and found evidence of negative selection in the coding sequences for most of the known functional domains. However, those authors found evidence of positive selection only in the immunostimulatory conformational epitope G and linear epitopes D, D′ and concluded that these segments and not others were under selection for immune escape. Using a different approach to study selection in natural BLV infection, that is, analysis of individual conserved and semi-conserved segments instead of analysis of the whole glycoprotein, we confirmed that residues in conformation epitope G are under positive selection but found no evidence of positive selection in segment C which comprises a large portion of linear epitopes D, D′. In contrast to their finding of no evidence for positive selection of residues within other segments of gp51, we found evidence that ND2 (which includes segment J) and epitope A at the C-terminal end of gp51 (which includes segment H) are undergoing positive selection. We believe that the difference between our reports attributes to the segment-based analysis reported here being a more sensitive method for identifying rare residues of BLV that are under selection but in otherwise highly conserved segments.
Lastly, we conclude that the consensus amino acid sequence constitutes a strong candidate from which a universal vaccine can be derived for use in countries where eradication by culling is not economically feasible. Two of the MEME motifs represent unique segments that are not contained within previously identified immune determinants. Based on their location relative to that of known functional and structural domains in other retroviral SU, we propose that one (segment K) of these newly identified segments is involved in the folding of native gp51 and the other (segment E) is a strong candidate for part of the receptor binding sequence. Notably, none of the conserved or semi-conserved segments include residues in conformational epitope H. Taken together the results suggest that globally dispersed variations in segments E and K and in epitope H sequences make them poor candidates for use in a peptide vaccine strategy. In contrast, highly conserved segment A, which is another strong candidate for the receptor binding site, contains previously identified neutralizing and T- cell determinants that suggest it is a good candidate for use in a peptide vaccine, one capable perhaps of eliciting neutralizing antibody responses.
All of the B-cell and T-cell determinants and neutralizing domains, and all but one (H) of the antigenic epitopes contain and overlap with the new segments reported here. The new semi-conserved segments overlap with conformation epitopes G and F, linear epitopes A and B-B′, neutralizing domains 2 and 3, CD4+ T-cell epitopes N5 and N11. Of the three amino acid differences between the consensus sequence and that of strain FLK, two residues (74 and 82) are in the CD8+ T-cell epitope N5 and in conformational epitope G and the third is in the D, D′ epitope. This low level of difference is in line with the unusually high fidelity of the BLV polymerase and high level of conservation seen across global isolates. The most conserved segments encompass amino acids in epitopes D–D′, E-E′, two CD8+ T-cell epitopes, neutralizing domain 1 and two CD4+ T-cell epitopes, suggesting that their consensus sequence has limited global variation and are prime candidates for development of an globally effective peptide vaccine.
Sequence motif discovery
MEME version 4.10.0 , a hidden Markov model based software, and DnaSP version 5.10 software  were used to identify segments that occur in a group of 256 sequences extracted from the NCBI nucleotide database and represent all known BLV env sequences. Seventy-one proviruses were from three East Asian countries (Myanmar, South Korea and Thailand), sixty-three were from six South American countries (Argentina, Boliva, Brazil, Peru, Paraguay and Uruguay), thirty-nine from Russia, thirty-four from Japan, twenty-six from four European countries (Belgium, Italy, Moldova and Poland), eighteen from three North American sites (Caribbean, Costa Rico and the United States), and five proviruses from Australia, Iran and the Ukraine combined (Additional file 1: Table S1). Sequences derived from PCR-amplification of proviruses using the nested primer sets related to those introduced by Fechner et al. in 1997 were excluded from the analysis because they comprise fragments of < 500 bp and encode only the central half of gp51 . The coding sequence for the 33 amino acid signal peptide was also excluded from analysis because the majority of the sequences in the database that encode the entire mature gp51 are derived from an 804 bp restriction fragment that does not contain signal peptide coding sequence.
The following steps were performed during the MEME and DnaSP analysis. First, a multiple sequence alignment was generated using ClustalW implemented in Geneious Pro 5.5.9 Software (Biomatters Ltd). Second, the aligned sequences were submitted to the MEME server (http://meme-suite.org/tools/meme). The MEME analysis was run in zoops (zero or one per sequence) mode with the maximum number of motifs set at 20. The optimal motif width range was set between 15 and 60 nucleotides (i.e., 5 and 20 amino acids in length) to reflect the length of the synthetic peptides commonly used in epitope mapping as well as the typical number of amino acid (aa) residues identified in antigenic determinants. The E-values are the estimated log likelihood ratio of a sequence pattern calculated by MEME analysis as a measure of how different each nucleotide in the segment (motif) is from an n-order Markov model matrix of the same width but randomized sequence. A segment with an E-value below e−9.2 has an estimated < 0.0001 probability that its sequence occurs randomly within the aligned input sequences. Third, the alignment was separately imported into the Conserved DNA Region module implemented in DnaSP Ver. 5.10.01 software and the minimum conservation threshold set at 80%. Lastly, the combined analyses were used to identify conserved segments of interest in the env genes.
Weblogo was then used to generate a quantitative graphical representation of the segments and sequence alignments. To estimate the level of nucleotide sequence divergence for conserved and variable segments, maximum composite likelihood model analysis (MEGA 5.2.2) was conducted as described . Synonymous and non-synonymous sites were identified using the DnaSP 5.0. Statistical analyses identifying synonymous and non-synonymous sites was performed using STATISTICA ver. 10 (StatSoft, Dell Software, USA). Specifically, the number of synonymous substitutions per synonymous site (dS), the number of non-synonymous substitutions per non-synonymous site (dN) and their variances were calculated and applied to a selection Z-test to evaluate whether the segments were under positive or purifying selection. For comparison of two paired, nonparametric groups of data points, dN versus dS, a Wilcoxon matched pairs test was used to calculate the p values. Based on the results of the first analyses, the 256 member sequence alignment was submitted to the MEME server again using zoops mode with the maximum number of motifs set at 25 and the optimal motif width range set between 60 and 99 nucleotides (i.e., 20 and 33 amino acids in length) and the motif block output was subjected to further analysis as described above.
The consensus amino acid sequence for residues 3–156 comprising the putative RBD of mature SU sequence derived in the MEME analysis was aligned with the analogous extracellular amino acid sequence of the two gammaretroviral SU whose crystal structure has been solved, e.g., residues 9–236 of the mature SU from Fr57 MLV isolate 57  and residues 4–207 of the mature SU from FeLV-B virus . Each alignment was submitted for molecular modeling  using the 2.0 Å structure of the Fr57 MLV RBD (1AOL) and the 2.5 Å structure of FeLV-B RBD (1LCS) as templates. Noting that the BLV envelope glycoprotein is a member of the HTLV-1 superfamily of envelope glycoproteins , residues downstream of BLV gp51 residue 156 were modeled based on the known structure of the only member of the HTLV-1 superfamily for which structure of the analogous residues downstream of the RBD is available, e.g., GP of the Zaire strain of Ebola virus. Alignments of the consensus BLV gp51 sequence and that of Ebola virus GP were submitted for molecular modeling  using the 3.4 Å structure of the pre-fusion GP1-GP2 trimer (3CSY)  and the 3.3 Å structure of the host-primed GP1 and GP2 complexed with the virus binding domain of its host cell fusion receptor Niemann-Pick C1 (5HJ3) . Visualization of the predicted structures and figure preparation were performed using the MolSoft ICM Browser. Conserved and semi-conserved segments were visualized on structure models of the envelope protein.
AP designed and performed bioinformatic and statistical analyses. LMA performed molecular modeling. AP, LMA analyzed and interpreted the data and the results. AP, LMA wrote the manuscript. All authors helped edit the paper. All authors read and approved the final manuscript.
The authors would like to acknowledge the funding of this work: this research was funded by KNOW (Leading National Research Centre) Scientific Consortium “Healthy Animal- Safe Food”, decision of Ministry of Science and Higher Education of Poland No. 05-1/KNOW2/2015.
The authors declare that they have no competing interests
Availability of data and material
Consent for publication
Ethics approval and consent to participate
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- King AMQ, Adams J, Carstens EB, Lefkowitz EJ. Virus Taxonomy: classification and nomenclature of viruses: ninth report of the ICTV. Amsterdam: Elsevier/Academic Press; 2012. p. 1344.Google Scholar
- Kettmann R, Burny A, Callebaut I, Droogmans L, Mammerickx M, Willems L, Portetelle D. Bovine leukemia virus. The retroviridae. New York: Plenum Press; 1994. p. 39–81.View ArticleGoogle Scholar
- Ghysdael J, Bruck C, Kettmann R, Burny A. Bovine Leukemia virus. Curr Top Microbiol Immunol. 1984;112:1–19.PubMedGoogle Scholar
- Temin HM. Origin and general nature of retroviruses. In: Levy J, editor. The retroviridae. New York: Plenum Press; 1992. p. 1–18.Google Scholar
- Zhao X, McGirr KM, Buehring GC. Potential evolutionary influences on overlapping reading frames in the bovine leukemia virus pXBL region. Genomics. 2007;89:502–11.View ArticlePubMedGoogle Scholar
- Willems L, Thienpont E, Kerkhofs P, Burny A, Mammerickx M, Kettmann R. Bovine leukemia virus an animal model for the study of intrastrain variability. J Virol. 1993;67:1086–9.PubMedPubMed CentralGoogle Scholar
- Burns DP, Desrosiers RC. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol. 1991;65(4):1843–54.PubMedPubMed CentralGoogle Scholar
- Overbaugh J, Rudensey LM, Papenhausen MD, Benveniste RE, Morton WR. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol. 1991;65(12):7025–31.PubMedPubMed CentralGoogle Scholar
- Johnson PR, Hamm TE, Goldstein S, Kitov S, Hirsch VM. The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. Virology. 1991;185(1):217–28.View ArticlePubMedGoogle Scholar
- Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science. 1988;242(4882):1168–71.View ArticlePubMedGoogle Scholar
- Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242(4882):1171–3.View ArticlePubMedGoogle Scholar
- Mansky LM, Temin HM. Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus. J Virol. 1994;68:494–9.PubMedPubMed CentralGoogle Scholar
- Camargos MF, Pereda A, Stancek D, Rocha MA, dos Reis JK, Greiser-Wilke I, Leite RC. Molecular characterization of the env gene from Brazilian field isolates of Bovine leukemia virus. Virus Genes. 2007;34(3):343–50.View ArticlePubMedGoogle Scholar
- Rodriguez SM, Golemba MD, Campos RH, Trono K, Jones LR. Bovine leukemia virus can be classified into seven genotypes: evidence for the existence of two novel clades. J Gen Virol. 2009;90:2788–97.View ArticlePubMedGoogle Scholar
- Hemmatzadeh F. Sequencing and phylogenetic analysis of gp51 gene of bovine leukaemia virus in Iranian isolates. Vet Res Commun. 2007;31(6):783–9.View ArticlePubMedGoogle Scholar
- Polat M, Takeshima SN, Hosomichi K, Kim J, Miyasaka T, Yamada K, Arainga M, Murakami T, Matsumoto Y, Barra Diaz V, Panei CJ, González ET, Kanemaki M, Onuma M, Giovambattista G, Aida Y. A new genotype of bovine leukemia virus in South America identified by NGS-based whole genome sequencing and molecular evolutionary genetic analysis. Retrovirology. 2016;13(1):4.View ArticlePubMedPubMed CentralGoogle Scholar
- Moratorio G, Obal G, Dubra A, Correa A, Bianchi S, Buschiazzo A, Cristina J, Pritsch O. Phylogenetic analysis of bovine leukemia viruses isolated in South America reveals diversification in seven distinct genotypes. Arch Virol. 2010;155(4):481–9.View ArticlePubMedGoogle Scholar
- Dube S, Abbott L, Dube DK, Dolcini G, Gutierrez S, Ceriani C, Juliarena M, Ferrer J, Perzova R, Poiesz BJ. The complete genomic sequence of an in vivo low replicating BLV strain. Virol J. 2009;6:120.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee E, Kim EJ, Ratthanophart J, Vitoonpong R, Kim BH, Cho IS, Song JY, Lee KK, Shin YK. Molecular epidemiological and serological studies of bovine leukemia virus (BLV) infection in Thailand cattle. Infect Genet Evol. 2016;41:245–54.View ArticlePubMedGoogle Scholar
- Yang Y, Kelly PJ, Bai J, Zhang R, Wang Ch. First molecular characterization of bovine leukemia virus infections in the Caribbean. PLoS ONE. 2016;11(12):e0168379.View ArticlePubMedPubMed CentralGoogle Scholar
- Polat M, Ohno A, Takeshima SN, Kim J, Kikuya M, Matsumoto Y, Mingala CN, Onuma M, Aida Y. Detection and molecular characterization of bovine leukemia virus in Philippine cattle. Arch Virol. 2015. https://doi.org/10.1007/s00705-014-2280-3.Google Scholar
- Matsumura K, Inoue E, Osawa Y, Okazaki K. Molecular epidemiology of bovine leukemia virus associated with enzootic bovine leukosis in Japan. Virus Res. 2011. https://doi.org/10.1016/j.virusres.2010.11.005.PubMedGoogle Scholar
- Yang Y, Fan W, Mao Y, Yang Z, Lu G, Zhang R, Zhang H, Szeto C, Wang C. Bovine leukemia virus infection in cattle of China: association with reduced milk production and increased somatic cell score. J Dairy Sci. 2016. https://doi.org/10.3168/jds.2015-10580.Google Scholar
- Rola-Łuszczak M, Pluta A, Olech M, Donnik I, Petropavlovskiy M, Gerilovych A, Vinogradova I, Choudhury B, Kuźmak J. The molecular characterization of bovine leukaemia virus isolates from Eastern Europe and Siberia and its impact on phylogeny. PLoS ONE. 2013. https://doi.org/10.1371/journal.pone.0058705.PubMedPubMed CentralGoogle Scholar
- Balić D, Lojkić I, Periškić M, Bedeković T, Jungić A, Lemo N, Roić B, Cač Z, Barbić L, Madić J. Identification of a new genotype of bovine leukemia virus. Arch Virol. 2012. https://doi.org/10.1007/s00705-012-1300-4.PubMedGoogle Scholar
- Pluta A, Rola-Łuszczak M, Kubiś P, Balov S, Moskalik R, Choudhury B, Kuźmak J. Molecular characterization of bovine leukemia virus from Moldovan dairy cattle. Arch Virol. 2017. https://doi.org/10.1007/s00705-017-3241-4.PubMedPubMed CentralGoogle Scholar
- Lee AJ, Kim EJ, Joung HK, Kim BH, Song JY, Cho IS, Lee KK, Yeun-Kyung Shin YK. Sequencing and phylogenetic analysis of the gp51 gene from Korean bovine leukemia virus isolates. Virol J. 2015. https://doi.org/10.1186/s12985-015-0286-4.Google Scholar
- Bruck C, Mathot S, Portetelle D, Berte C, Herion P, Burny A. Monoclonal antibodies define eight independent antigenic regions on the bovine leukemia virus (BLV) envelope glycoprotein gp51. Virology. 1982;122(2):342–52.View ArticlePubMedGoogle Scholar
- Portetelle D, Dandoy C, Burny A, Zavada J, Siakkou H, Gras-Masse H, Drobecq H. Tartar A Synthetic peptides approach to identification of epitopes on bovine leukemia virus envelope glycoprotein gp51. Virology. 1989. https://doi.org/10.1016/0042-6822(89)90038-x.Google Scholar
- Callebaut I, Burny A, Krchnák V, Gras-Masse H, Wathelet B, Portetelle D. Use of synthetic peptides to map sequential epitopes recognized by monoclonal antibodies on the bovine leukemia virus external glycoprotein. Virology. 1991;185(1):48–55.View ArticlePubMedGoogle Scholar
- Callebaut I, Voneche V, Mager A, Fumiere O, Krchnak V, Merza M, Zavada J, Mammerickx M, Burny A, Portetelle D. Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51. J Virol. 1993;67:5321–7.PubMedPubMed CentralGoogle Scholar
- Zhao X, Buehring GC. Natural genetic variations in bovine leukemia virus envelope gene: possible effects of selection and escape. Virology. 2007;366:150–65.View ArticlePubMedGoogle Scholar
- Bai L, Takeshima SN, Isogai E, Kohara J, Aida Y. Novel CD8(+) cytotoxic T cell epitopes in bovine leukemia virus with cattle. Vaccine. 2015. https://doi.org/10.1016/j.vaccine.2015.10.128.PubMed CentralGoogle Scholar
- National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville 2017. https://www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi?uid=306850 and https://www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi?hslf=1&uid=cd09948&#seqhrch. Accessed 1 July 2017.
- Johnston ER, Albritton LM, Radke K. Envelope proteins containing single amino acid substitutions support a structural model of the receptor-binding domain of bovine leukemia virus surface protein. J Virol. 2002;76(21):10861–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Miller JM, Miller LD, Olson C, Gillette KG. Virus-like particles in phytohemagglutinin-stimulated lymphocyte cultures with reference to bovine lymphosarcoma. J Natl Cancer Inst. 1969;43(6):1297–305.PubMedGoogle Scholar
- Esteban EN, Poli M, Poiesz B, Ceriani C, Dube S, Gutierrez S, Dolcini G, Gagliardi R, Perez S, Lützelschwab C, Feldman L, Juliarena MA. Bovine leukemia virus (BLV), proposed control and eradication programs by marker assisted breeding of genetically resistant cattle. In: Rechi LJ, editor. Animal genetics. Hauppauge, NY: Nova Science Publishers Inc; 2009. p. 1–24.Google Scholar
- Juliarena MA, Lendez PA, Gutierrez SE, Forletti A, Rensetti DE, Ceriani MC. Partial molecular characterization of different proviral strains of bovine leukemia virus. Arch Virol. 2013;158:63–70.View ArticlePubMedGoogle Scholar
- Altanerova V, Holicova D, Kucerova L, Altaner C, Lairmore MD, Boris-Lawrie K. Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits. Virology. 2004;329(2):434–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Gutiérrez G, Rodríguez SM, Brogniez A, Gillet N, Golime R, Burny A, Jaworski JP, Alvarez I, Vagnoni L, Trono K, Willems L. Vaccination against δ-retroviruses: the bovine leukemia virus paradigm. Viruses. 2014. https://doi.org/10.3390/v6062416.Google Scholar
- Sugimoto M, Ohishi K, Ikawa Y. Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. Ther Immunol. 1994;1(5):297–301.PubMedGoogle Scholar
- Ohishi K, Kabeya H, Amanuma H, Onuma M. Peptide-based bovine leukemia virus (BLV) vaccine that induces BLV-Env specific Th-1 type immunity. Leukemia. 1997;11(Suppl 3):223–6.PubMedGoogle Scholar
- Woon HG, Scott GM, Yiu KL, Miles DH, Rawlinson WD. Identification of putative functional motifs in viral proteins essential for human cytomegalovirus DNA replication. Virus Genes. 2008. https://doi.org/10.1007/s11262-008-0255-8.PubMedGoogle Scholar
- Kolb AW, Schmidt TR, Dyer DW, Brandt CR. Sequence variation in the herpes simplex virus U(S)1 ocular virulence determinant. Invest Ophthalmol Vis Sci. 2011. https://doi.org/10.1167/iovs.10-7032.Google Scholar
- Gallaher WR, Ball JM, Garry RF, Martin-Amedee AM, Montelaro RC. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res Hum Retroviruses. 1995;11(2):191–202.View ArticlePubMedGoogle Scholar
- Johnston ER, Radke K. The SU and TM envelope protein subunits of bovine leukemia virus are linked by disulfide bonds, both in cells and in virions. J Virol. 2000;74(6):2930–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu SR, Sjöberg M, Wallin M, Lindqvist B, Ekström M, Hebert H, Koeck PJ, Garoff H. Turning of the receptor-binding domains opens up the murine leukaemia virus Env for membrane fusion. EMBO J. 2008;27:2799–808.View ArticlePubMedPubMed CentralGoogle Scholar
- Kuo CW, Mirsaliotis A, Brighty DW. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process. J Immunol. 2011. https://doi.org/10.4049/jimmunol.1100070.PubMed CentralGoogle Scholar
- Battini JL, Danos O, Heard JM. Receptor-binding domain of murine leukemia virus envelope glycoproteins. J Virol. 1995;69(2):713–9.PubMedPubMed CentralGoogle Scholar
- Kim FJ, Manel N, Garrido EN, Valle C, Sitbon M, Battini JL. HTLV-1 and -2 envelope SU subdomains and critical determinants in receptor binding. Retrovirology. 2004;2(1):41.View ArticleGoogle Scholar
- Monti G, Schrijver R, Beier D. Genetic diversity and spread of Bovine leukaemia virus isolates in Argentine dairy cattle. Arch Virol. 2005;150(3):443–58.View ArticlePubMedGoogle Scholar
- Bailey TL, Williams N, Misleh C, Li WW. MEME: discovering and analyzing DNA and protein sequence motifs. Institute of Molecular Bioscience, The University of Queensland, St Lucia. Nucleic Acids Res. 2006. https://doi.org/10.1093/nar/gkl198.Google Scholar
- Librado P, Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics. 2009;25:1451–2.View ArticlePubMedGoogle Scholar
- Fechner H, Blankenstein P, Looman AC, Elwert J, Geue L, Albrecht C, Kurg A, Beier D, Marquardt O, Ebner D. Provirus variants of the bovine leukemia virus and their relation to the serological status of naturally infected cattle. Virology. 1997;237(2):261–9.View ArticlePubMedGoogle Scholar
- Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28:2731–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Fass D, Davey RA, Hamson CA, Kim PS, Cunningham JM, Berger JM. Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution. Science. 1997;277(5332):1662–6.View ArticlePubMedGoogle Scholar
- Barnett AL, Wensel DL, Li W, Fass D, Cunningham JM. Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus. J Virol. 2003;77(4):2717–29.View ArticlePubMedPubMed CentralGoogle Scholar
- Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL Workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22:195–201.View ArticlePubMedGoogle Scholar
- Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008. https://doi.org/10.1038/nature07082.Google Scholar
- Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE Jr, Chandran K, Saphire EO. Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies. MBio. 2016. https://doi.org/10.1128/mbio.02154-15.PubMedPubMed CentralGoogle Scholar